Adding preoperative chemoradiotherapy for gastric cancer shows no survival benefit – EORTC
EORTC – European Organisation for Research and Treatment of Cancer posted the following on LinkedIn:
“A recent EORTC study shows that adding preoperative chemoradiotherapy to perioperative chemotherapy does not improve overall survival compared to perioperative chemotherapy alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
Authors: Trevor Leong, M.D., B. Mark Smithers, M.D., Michael Michael, M.D., Karin Haustermans, M.D., Rebecca Wong, M.D., Val Gebski, M.Stat., Rachel L. O’Connell, Ph.D., John Zalcberg, M.D., Alex Boussioutas, M.D., Michael Findlay, M.D., David Willis, M.Tech., Alisha Moore, B.Med.Rad.Sci., William K. Murray, M.D., Florian Lordick, M.D., Chris O’Callaghan, D.V.M., Ph.D., Carol Swallow, M.D., Gail Darling, M.D., Danielle Miller, M.P.H., Andrew Strickland, M.D., Moishe Liberman, M.D., Laurent Mineur, M.D., and John Simes, M.D, for the Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023